Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Brentuximab vedotin

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Brentuximab vedotin: Sponsors, patents, clinical trial progress

Brentuximab vedotin is an investigational drug.

There have been 133 clinical trials for Brentuximab vedotin. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2014.

The most common disease conditions in clinical trials are Lymphoma, Hodgkin Disease, and Lymphoma, Non-Hodgkin. The leading clinical trial sponsors are Seattle Genetics, Inc., Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are thirty-two US patents protecting this investigational drug and five hundred and twenty-nine international patents.

Recent Clinical Trials for Brentuximab vedotin
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaNational Cancer Institute (NCI)Phase 3
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell LymphomaSeattle Genetics, Inc.Phase 2
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin LymphomaUniversity of ColognePhase 2

See all Brentuximab vedotin clinical trials

Clinical Trial Summary for Brentuximab vedotin

Top disease conditions for Brentuximab vedotin
Top clinical trial sponsors for Brentuximab vedotin

See all Brentuximab vedotin clinical trials

US Patents for Brentuximab vedotin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Brentuximab vedotin   Start Trial Encapsulated agents and methods of making and using thereof University of Georgia Research Foundation, Inc. (Athens, GA)   Start Trial
Brentuximab vedotin   Start Trial Substituted urea derivatives and pharmaceutical uses thereof SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)   Start Trial
Brentuximab vedotin   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.